Yubico has moved forward with several initiatives that will grow its distribution network in the EMEA and APAC regions. In that regard, the company has expanded the scope of its partnership with Infinigate, and launched YubiEnterprise Subscription services in Europe and Asia.
The new arrangement with Infinigate will extend channel coverage to the UK, and builds on the existing relationship between Yubico and Infinigate. The two companies have previously worked together as channel partners in other European countries.
CRN recently named Infinigate as its 2019 UK Security Distributor of the Year. However, Yubico, indicated that the presence of Infinigate will not affect its relationship with Distology, which is its previous channel partner in the UK. Instead, it confirmed that Distology and Infinigate will both be part of its market strategy in the country.
“Yubico is an exciting vendor for us,” said Infinigate UK Managing Director Justin Griffiths. “Enabling our partners to provide their customers with cutting-edge security is Infinigate UK’s primary focus, and Yubico powers us to deliver broader solutions and even stronger security.”
In other news, Yubico officially brought its YubiEnterprise Subscription service to the EMEA and APAC territories on September 23. YubiEnterprise Subscription is designed for larger organizations that want to provide security keys for their employees, giving them a predictable per month per employee pricing model that makes it easy to upgrade to new YubiKey models. The service debuted in the US and Canada back in February.
Yubico has also continued to add to its network with a Yubico Partner Program that makes it easier for companies to become certified YubiKey resellers. The Partner Program made its way to the EMEA and APAC regions earlier this year.
Yubico noted that the increase in remote work activity has created more demand for strong authentication options to protect sensitive materials. The company has previously warned about an increase in social engineering attacks during the COVID-19 pandemic.